Faculty Bibliography

Asian rhinoplasty presents unique challenges to the surgeon. The aesthetic goals should be tailored for the ethnicity and culture of the individual patient. Unlike typical Caucasian rhinoplasty, primary Asian rhinoplasty is frequently augmentation rhinoplasty. Alloplastic implants have had a long history of safety in Asia, but many patients are not suitable for or not agreeable to the use of alloplastic materials and autologous costal cartilage should be considered. This procedure is safe and reliable when these techniques are properly executed.

PURPOSE OF REVIEW: Successful rhinoplasty requires a detailed understanding of the nasal structure needed to produce a functional and aesthetically pleasing nose. Recent advances in surgical technique have focused on cartilage repositioning and reshaping, often with the use of cartilage grafting. RECENT FINDINGS: Newer techniques for strengthening the middle vault, stabilizing the base, and modifying the lateral crura are presented, as well as the M-arch model, a modification of the tripod concept. SUMMARY: Technical advances in rhinoplasty provide numerous options for reconstruction and reshaping of the nose.

Chemodenervation with botulinum toxin has become an integral part of the facial plastic armamentarium. Although eyebrow and eyelid cosmetic deformities and asymmetries have traditionally been treated by surgical intervention, Botox can now be incorporated effectively into the surgical plan. When the surgeon has a complete understanding of facial anatomy and muscular interactions, Botox can be used as a primary treatment of the periorbital region or as an adjunct to surgical procedures of the periorbital region.

PURPOSE: To establish the safety and toxicity profile of daily gefitinib with radiation alone or with concurrent chemoradiotherapy in previously untreated patients with locally advanced squamous cell head and neck cancer (LAHNC). PATIENTS AND METHODS: Patients with intermediate-stage LAHNC were treated with concomitant boost radiation (RT) alone with escalating doses of daily gefitinib (250 or 500 mg; cohort I). Once a safety profile was determined with RT alone, patients with high-risk disease were then treated with daily gefitinib (250 or 500 mg), weekly cisplatin (CDDP; 30 mg/m2), and once-daily RT (cohort II). Patients also received post-RT gefitinib at 250 mg daily for a period of up to 2 years. RESULTS: Twenty-three patients were enrolled and assessable for toxicity. No dose-limiting toxicities (DLTs) were observed in patients treated in cohort I at either 250 or 500 mg of gefitinib daily with concomitant boost RT to 72 Gy. In patients receiving chemoradiotherapy and gefitinib (cohort II), DLTs included one grade 4 diarrhea and one grade 4 neutropenic fever. Fifteen patients started maintenance gefitinib, and eight (53%) experienced grade 1 to 2 acne-like skin rash and diarrhea, but no grade 3 or 4 toxicity occurred. CONCLUSION: Gefitinib (250 or 500 mg daily) was well tolerated with concomitant boost RT or concurrent chemoradiotherapy with weekly CDDP. Protracted administration of gefitinib for up to 2 years at 250 mg daily was also tolerated well.

OBJECTIVE: To examine the Epstein-Barr virus (EBV) IgA and DNA assays as a screening tool for nasopharyngeal carcinoma (NPC) in a nonendemic US population. STUDY DESIGN AND SETTING: Prospective study performed at a teaching hospital in New York City. There were two groups of 155 patients: new NPC patients and controls. An otolaryngologic examination and serial blood testing for serologic markers were performed. RESULTS: Sensitivity and specificity of EBV IgA and DNA assays were determined. Screening scenarios involving series and parallel testing were evaluated to determine economic feasibility. Series testing provided a sensitivity, specificity, and positive and negative predictive values of 90.6, 93.5, 78.4, and 97.5 percent, respectively. Parallel testing increased the sensitivity to 100 percent. CONCLUSION: NPC screening in a high-risk, nonendemic population using EBV-specific serologic markers is effective. Series testing is a statistically sound and economically feasible strategy. SIGNIFICANCE: The development of a cost-effective NPC screening strategy in a high-risk, nonendemic population in the United States.

OBJECTIVES: The safety of the Otologics Fully-Implantable MET Ossicular Stimulator was assessed in adult patients with bilateral moderate to severe sensorineural hearing loss. METHODS: Surgical implantation of the ossicular stimulator was performed. A repeated-measure, within-subjects design assessed safety and aided sound field thresholds and speech performances with the subject's own, appropriately fitted, walk-in hearing aid(s) and the Otologics Fully-Implantable MET Ossicular Stimulator. RESULTS: Twenty patients were implanted and activated as part of the Phase I clinical trial. Results demonstrated 10-20 dB of functional gain across audiometric frequencies. Pure tone averages and monaural word recognition scores were slightly better for the walk-in-aided condition, while patient benefit scales favored the postoperative implant-aided conditions. CONCLUSION/SIGNIFICANCE: Although monaural word scores and aided thresholds favored the walk-in-aided condition, preliminary results indicate that the Otologics MET Fully-Implantable Ossicular Stimulator is an alternative to currently available hearing aids in patients with sensorineural hearing loss.

Classic rhizomelic chondrodysplasia punctata is a rare, autosomal, recessively inherited disorder that is characterized by proximal shortening of the limbs, punctuate calcifications of the epiphyses, cataracts, developmental delay, and early lethality. A distinctive biochemical profile is characteristic for each of the several defects of peroxisomal metabolism. Recently, cases have been described that were not associated with peroxisomal dysfunction. These cases were found to be secondary to teratogen exposure or maternal conditions. Since 1993, there have been 9 reported cases of neonates with rhizomelic chondrodysplasia punctata who were born to mothers with connective tissue disease. We followed a newborn boy with features suggestive of rhizomelic chondrodysplasia punctata whose biochemical studies failed to demonstrate a defect in either plasmalogen or cholesterol biosynthesis. His mother developed systemic lupus erythematosus 8 months after delivery. This case is compared with the previously reported 9 cases from the literature and is instructive in demonstrating a lesser known effect of maternal autoantibodies on the fetus.

CONCLUSIONS: Guild's initial 231 word report was the source of a stream of positive consequences; the glomus story is a paradigm of the utility of basic science. BACKGROUND: The glomus tumor has had a number of different names, including glomus jugulare, glomus tympanicum, nonchromaffin paraganglioma, and carotid body tumor. Although they have occurred throughout the ages, glomus tumors were neither recognized nor understood until Harry Rosenwasser read Stacy Guild's report of 1941. MATERIALS AND METHODS: The pertinent literature from the 18th century to the present was reviewed. RESULTS: Stacy Guild's pursuit of basic scientific knowledge laid the foundation for a chain of clinical and scientific advances that continue to the present and will continue to have positive effects into the future. Guild's brief basic science note of 1941 was used through the scholarship of Rosenwasser to define a clinical entity that had not been recognized. This new nosology, rapidly adopted worldwide, provided a biological basis for the rational grouping of patients and analysis of their ills. Subsequent to this, it was noted that many of these tumors occurred in families, apparently transmitted as an autosomal dominate but occurring primarily in the males. Further study based on these observations led to the identification of a genetic mechanism of inheritance: genomic imprinting. A further advance of the synergetic relationship between the environment - oxygen tension/altitude - and the mutation explains Guild's 1953 observations that all patients, without any sexual predominance, have glomus bodies but not all have tumors.